Jove
Visualize
Contact Us

Related Experiment Videos

Renal involvement in systemic sclerosis

V D Steen1

  • 1Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania 15261.

Clinics in Dermatology
|April 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SYSTEMIC SCLEROSIS RELATED CALCINOSIS: PATIENTS PROVIDE WHAT SPECIALISTS WANT TO LEARN.

The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society·2016
Same author

Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters.

Clinical and experimental rheumatology·2014
Same author

Recognition of pulmonary hypertension in the rheumatology community: lessons from a Quality Enhancement Research Initiative.

Clinical and experimental rheumatology·2013
Same author

Is exercise-induced pulmonary hypertension ready for prime time in systemic sclerosis?

International journal of clinical practice. Supplement·2010
Same author

Development of a provisional core set of response measures for clinical trials of systemic sclerosis.

Annals of the rheumatic diseases·2007
Same author

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.

Annals of the rheumatic diseases·2006
Same journal

Letter to the editor in reply to "Ethics of Rising Trends in Dermatology Publications Using Large-Scale Databases".

Clinics in dermatology·2026
Same journal

Ethics of suggesting image-guided superficial radiation therapy on the pathology report.

Clinics in dermatology·2026
Same journal

Tanorexia: The Psychodermatology of Compulsive Tanning.

Clinics in dermatology·2026
Same journal

Ear manifestations of connective tissue diseases: A dermatologic, histopathologic, and clinicopathologic review.

Clinics in dermatology·2026
Same journal

Discovery of an intravenous drug injection site: A meticulous cutaneous examination provides the forensic dermatologic clue to a diagnosis of homicide.

Clinics in dermatology·2026
Same journal

Sherlock Holmes and the mystery of the deadly diet.

Clinics in dermatology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Systemic sclerosis renal crisis (SRC) is a severe complication characterized by malignant hypertension and kidney failure. Early treatment with angiotensin-converting enzyme (ACE) inhibitors significantly improves survival and kidney function in SRC patients.

Area of Science:

  • Nephrology
  • Rheumatology
  • Internal Medicine

Background:

  • Systemic sclerosis (SSc) can lead to renal crisis (SRC), a life-threatening complication.
  • SRC presents with malignant hypertension, hyperreninemia, azotemia, and microangiopathic hemolytic anemia.
  • Historically, SRC had a poor prognosis, often leading to death.

Purpose of the Study:

  • To summarize the characteristics and treatment outcomes of systemic sclerosis renal crisis.
  • To highlight the efficacy of angiotensin-converting enzyme (ACE) inhibitors in managing SRC.
  • To emphasize the importance of early diagnosis and treatment for optimal patient outcomes.

Main Methods:

  • Review of clinical data and outcomes for patients with systemic sclerosis and renal crisis.

Related Experiment Videos

  • Analysis of treatment responses to angiotensin-converting enzyme (ACE) inhibitors.
  • Evaluation of survival rates and renal function in treated patients.

    • Main Results:

    • Angiotensin-converting enzyme (ACE) inhibitors have transformed the prognosis of SRC.
    • Most patients treated with ACE inhibitors experience improved survival.
    • Reduced need for dialysis and potential for dialysis discontinuation (6-18 months) are observed.

    Conclusions:

    • Prompt diagnosis and aggressive treatment of SRC with ACE inhibitors are crucial.
    • Early intervention with ACE inhibitors significantly improves outcomes for systemic sclerosis patients with renal crisis.
    • Optimized management strategies enhance survival and renal recovery in SRC.